Assessing Benefits and Harms of Opioid Therapy for Chronic Pain

Clinician Outreach and Communication Activity (COCA) Call
August 3, 2016
Accreditation Statements

CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians. The Centers for Disease Control and Prevention designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center’s Commission on Accreditation. This activity provides 1.0 contact hour.

IACET CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 1.0 CEU’s for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designed for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to 1.0 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. CDC provider number 98614.

CPE: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is a designated event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is 0387-0000-16-150-L04-P and enduring 0387-0000-16-150-H04-P course category. Course Category: This activity has been designated as knowledge-based. Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor

AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing education in the jurisdictions which recognize AAVSB RACE approval. Please contact the AAVSB RACE Program at race@aavsb.org if you have any comments/concerns regarding this program’s validity or relevancy to the veterinary profession.

CPH: The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credit for this program.
Continuing Education Disclaimer

CDC, our planners, presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters, with the exception of Dr. Mark Sullivan and Dr. Jane Ballantyne. They would like to disclose that their employer, the University of Washington, received a contract payment from the Centers for Disease Control and Prevention. Dr. Sullivan would like to disclose that he is consulting with Chrono Therapeutics concerning development and testing of an opioid taper device.

Planners have reviewed content to ensure there is no bias.

This presentation will not include any discussion of the unlabeled use of a product or products under investigational use.
Objectives

At the conclusion of this session, the participant will be able to:

- Describe the evidence for the benefits and harms of opioid therapy for chronic pain outside of active cancer treatment, palliative, and end-of-life care.

- Review methods for setting goals for pain management with patients.

- Summarize factors that increase risk for harm and how to assess for such factors.

- Review methods for assessing patients’ pain and function, and for conducting appropriate follow-up.
# Save-the-Dates

Mark your calendar for the upcoming opioid prescribing call

<table>
<thead>
<tr>
<th>Call No.</th>
<th>Date</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>June 22</td>
<td>Guideline for Prescribing Opioids for Chronic Pain</td>
</tr>
<tr>
<td>2</td>
<td>July 27</td>
<td>Non-Opioid Treatments</td>
</tr>
<tr>
<td>3</td>
<td>August 3</td>
<td>Assessing Benefits and Harms of Opioid Therapy</td>
</tr>
<tr>
<td>4</td>
<td>August 17</td>
<td>Dosing and Titration of Opioids</td>
</tr>
</tbody>
</table>
TODAY’S PRESENTER

Mark Sullivan, MD, PhD
Professor, Psychiatry and Behavioral Sciences
Anesthesiology and Pain Medicine
Bioethics and Humanities
University of Washington
Jane Ballantyne, MD, FRCA
Professor, Anesthesiology and Pain Medicine
Director, Pain Fellowship
University of Washington
Disclaimer

The findings and conclusions in this presentation are those of the author(s) and do not necessarily represent the views of the Centers for Disease Control and Prevention/the Agency for Toxic Substances and Disease Registry
CDC Guideline for Prescribing Opioids for Chronic Pain: Assessing Benefits and Harms of Opioid Therapy

Deborah Dowell, MD, MPH

August 3, 2016
CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016


U.S. Department of Health and Human Services
Centers for Disease Control and Prevention
JAMA: The Journal of American Medical Association

Deborah Dowell, Tamara Haegerich, and Roger Chou

CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016

Published online March 15, 2016
Difficult to predict benefits and harms of long-term opioid use in individual patients

• Unclear whether there are long-term benefits

• Short-term benefits
  – Small to moderate for pain
  – Inconsistent for function

• Serious risks include opioid use disorder and overdose

• Risk assessment instruments do not consistently predict opioid abuse or misuse
Opioids not first-line or routine therapy for chronic pain

• Nonpharmacologic therapy and nonopioid pharmacologic therapy are preferred for chronic pain.
• Clinicians should consider opioid therapy only if expected benefits for both pain and function are anticipated to outweigh risks to the patient.
• If opioids are used, they should be combined with nonpharmacologic therapy and nonopioid pharmacologic therapy, as appropriate.

(Recommendation category: A; Evidence type: 3)
Establish and measure progress toward goals

• Before starting opioid therapy for chronic pain, clinicians should establish treatment goals with all patients, including realistic goals for pain and function, and should consider how therapy will be discontinued if benefits do not outweigh risks.

• Clinicians should continue opioid therapy only if there is clinically meaningful improvement in pain and function that outweighs risks to patient safety.

(Recommendation category: A; Evidence type: 4)
Before starting long-term opioids for chronic pain

1. Determine whether expected benefits for both pain and function are anticipated to outweigh risks to the patient
2. Establish treatment goals*
3. Set criteria for stopping or continuing opioids
4. Have an “exit strategy” for discontinuing therapy

*For patients already receiving opioids, establish goals for continued treatment
Assessing likely benefits of opioid therapy for individual patients

• Consider diagnosis (insufficient evidence for long-term benefits in headache, fibromyalgia, nonspecific back pain)

• Consider patient goals
  – Opioids might reduce pain in the short term
  – Opioids might reduce intermittent exacerbations of pain
  – Opioids might not reduce pain effectively long term
  – Opioids unlikely to eliminate pain
  – No demonstrated long-term improvement in function
Evaluate and address risks for opioid-related harms

• Before starting and periodically during continuation of opioid therapy, clinicians should evaluate risk factors for opioid-related harms.
• Clinicians should incorporate into the management plan strategies to mitigate risk, including considering offering naloxone when factors that increase risk for opioid overdose, such as history of overdose, history of substance use disorder, higher opioid dosages (>50 MME/day), or concurrent benzodiazepine use, are present.

(Recommendation category: A; Evidence type: 4)
Assessing for mental health conditions

• Treatment for depression may decrease overdose risk when opioids are used

• Assess for anxiety, PTSD, and depression using validated tools, e.g.,
  – Generalized Anxiety Disorder (GAD)-7
  – Patient Health Questionnaire (PHQ)-9
  – PHQ-4
Assessing for substance use disorder

• Ask patients about their drug and alcohol use
  – Single screening questions can be used, e.g., “How many times in the past year have you used an illegal drug or used a prescription medication for nonmedical reasons?”
  – Validated screening tools can also be used, e.g.,
    • Drug Abuse Screening Test (DAST)
    • Alcohol Use Disorders Identification Test (AUDIT)
• Use PDMP data and urine drug testing to assess for concurrent substance use
Establishing treatment goals

• Include goals for both pain and function
  – Improvement in physical function not always realistic (e.g., catastrophic spinal injury)
  – Function can include emotional and social dimensions
• Set realistic, meaningful functional goals (e.g., walk around block)
• Set goals for objective improvement
• Use validated instruments such as the PEG* Assessment Scale
  – Clinically meaningful improvement: >30% improvement

* Pain average, interference with Enjoyment of life, and interference with General activity (PEG) Assessment Scale
3-item (PEG) Assessment Scale

1. What number best describes your pain on average in the past week? (from 0=no pain to 10=pain as bad as you can imagine)

2. What number best describes how, during the past week, pain has interfered with your enjoyment of life? (from 0=does not interfere to 10=completely interferes)

3. What number best describes how, during the past week, pain has interfered with your general activity? (from 0=does not interfere to 10=completely interferes)

PEG = Pain average, interference with Enjoyment of life, and interference with General activity
Re-evaluate benefits and harms of opioids, and continue therapy only as a deliberate decision

- Clinicians should evaluate benefits and harms with patients within 1 to 4 weeks of starting opioid therapy for chronic pain or of dose escalation.
- Clinicians should evaluate benefits and harms of continued therapy with patients every 3 months or more frequently.
- If benefits do not outweigh harms of continued opioid therapy, clinicians should optimize other therapies and work with patients to taper opioids to lower dosages or to taper and discontinue opioids.

(Recommendation category: A; Evidence type: 4)
How often to evaluate patients to assess benefits and harms of long-term opioid use?

• Within 1 - 4 weeks of starting or increasing dosage
  – Within 1 week when
    • Starting or increasing ER/LA opioids
    • Total daily opioid dosage ≥50 MME/day
  – Within 3 days when starting or increasing methadone
• Regularly reassess at least every 3 months
• Reassess patients exposed to greater risk more frequently
  – Depression or other mental health conditions
  – History of substance use disorder or overdose
  – Taking ≥50 MME/day or other CNS depressants
Before continuing long-term opioids for chronic pain, ask

• Do opioids continue to meet treatment goals?
  – Progress toward individual patient goals?
  – Sustained, meaningful improvement in pain and function?
• Are there adverse events or early warning signs?
  – Over-sedation or overdose risk (if yes, taper dose)
  – Signs of opioid use disorder (if yes, treat or refer)
• Do benefits continue to outweigh risks?
• Can dosage can be reduced?
• Can opioids can be discontinued?
Connect With Us

Find more information on drug overdose and the Guideline:

- [www.cdc.gov/drugoverdose](http://www.cdc.gov/drugoverdose)
- [www.cdc.gov/drugoverdose/prescribing/guideline](http://www.cdc.gov/drugoverdose/prescribing/guideline)

Are you on Twitter?

- Follow [@DebHouryCDC](https://twitter.com/DebHouryCDC) and [@CDCInjury](https://twitter.com/CDCInjury) for useful information and important Guideline updates.

Find out more about Injury Center social media:

- [www.cdc.gov/injury/socialmedia](http://www.cdc.gov/injury/socialmedia)
CDC Guideline for Prescribing Opioids for Chronic Pain

ASSESSING BENEFITS AND HARMS OF OPIOID THERAPY

Mark Sullivan, MD, PHD
Professor, Psychiatry and Behavioral Sciences
Anesthesiology and Pain Medicine
Bioethics and Humanities
University of Washington, Seattle WA

Jane Ballantyne, MD, FRCA
Professor, Anesthesiology and Pain Medicine
Director, Pain Fellowship
University of Washington, Seattle WA
Ms. Christie is a 46 year old woman who has had fibromyalgia for the past three years. She was sent by her primary care provider to a rheumatologist who diagnosed fibromyalgia after a physical exam and an extensive series of blood tests.

Her primary care provider treated her with gabapentin 300mg qAM and 600mg qHS with moderately good results. She continued to have moderate 5/10 pain, but she was able to continue her job as a receptionist and her role as wife and mother to two high-school students.
Opioids not first-line or routine therapy for chronic pain

- Nonpharmacologic therapy and nonopioid pharmacologic therapy are preferred for chronic pain.
- Clinicians should consider opioid therapy only if expected benefits for both pain and function are anticipated to outweigh risks to the patient.
- If opioids are used, they should be combined with nonpharmacologic therapy and nonopioid pharmacologic therapy, as appropriate.

(Recommendation category: A; Evidence type: 3)
• “Evidence is insufficient to determine the effectiveness of long-term opioid therapy for improving chronic pain and function. Evidence supports a dose-dependent risk for serious harms.”
• Chou R et al Annals Intern Med 2015; 162:276-86
Opioid analgesics are commonly used for the treatment of fibromyalgia (FM) despite multiple treatment guidelines that recommend against the use of long-term opioid therapy.

- American Pain Society and the American Academy of Pain Medicine
- American Academy of Neurology
- European League Against Rheumatism
- Canadian Pain Society and the Canadian Rheumatology Association
- British Pain Society
Cochrane 2014 review concludes there is “no evidence at all” of oxycodone efficacy for fibromyalgia.

Tramadol may be effective in the treatment of FM but it is a weak opioid receptor agonist, and its efficacy in FM is likely related to its action as a serotonin-norepinephrine reuptake inhibitor.
Three months before today’s visit, Ms. Christie was rear-ended when stopped at a stoplight. She suffered a significant exacerbation of her fibromyalgia. She reported severe 8/10 pain in the ED immediately after the crash. She had no fractures, but was diagnosed with neck and back sprain. At that time she was prescribed oxycodone 5mg every 4 hours as needed for pain.

She continued to complain of severe 7/10 widespread pain despite taking 20mg oxycodone when she saw her primary care provider 2 weeks after the crash. Furthermore, she said that she was no longer able to do her job or fulfill her responsibilities at home.
Establish and measure progress toward goals

• Before starting opioid therapy for chronic pain, clinicians should establish treatment goals with all patients, including realistic goals for pain and function, and should consider how therapy will be discontinued if benefits do not outweigh risks.

• Clinicians should continue opioid therapy only if there is clinically meaningful improvement in pain and function that outweighs risks to patient safety.

(Recommendation category: A; Evidence type: 4)
She asked her primary care provider to increase her oxycodone dose to improve her pain and function level. Her primary care provider wanted to help her keep her job, so he wrote for oxycodone ER 20mg twice a day. When he checked in with her a week later, she reported feeling better and was getting back to work.
It is best to establish goals before embarking on a course of long-term opioid therapy, including criteria of success and failure.

Focus on achievement of life goals. Do not accept the goal of “no pain” or the goal of “less pain” in isolation from life goals.

If patient resists, ask “how would your life be different if you had significantly less pain?” Then explain that this is the life you will aim for together, which may or may not involve significant pain reduction.
• Measuring pain intensity alone is not adequate
  • wrong goals
  • wrong patients
  • wrong understanding

• Need multidimensional assessment
  • Function, both physical and role, personal activity
  • Sleep, depression, anxiety
  • Is life moving forward again?
  • http://paintracker.uwmedicine.org
Re-evaluate benefits and harms of opioids, and continue therapy only as a deliberate decision

- Clinicians should evaluate benefits and harms with patients within 1 to 4 weeks of starting opioid therapy for chronic pain or of dose escalation.
- Clinicians should evaluate benefits and harms of continued therapy with patients every 3 months or more frequently.
- If benefits do not outweigh harms of continued opioid therapy, clinicians should optimize other therapies and work with patients to taper opioids to lower dosages or to taper and discontinue opioids.

(Recommendation category: A; Evidence type: 4)
MEASURING PROGRESS IN RESPONSE TO LONG-TERM OPIOID THERAPY

• Short-term and long-term opioid therapy are different therapies, even if same meds used

• Short-term response (weeks-months) does not predict long-term response (months-years)

• Patients themselves tend to overestimate the benefit of therapy based on experiences with starting and stopping opioid therapy

• Pay attention to patients’ report of current level of pain and function, but don’t be distracted by claims that “I would be much worse without these opioids”
Evaluate and address risks for opioid-related harms

• Before starting and periodically during continuation of opioid therapy, clinicians should evaluate risk factors for opioid-related harms.

• Clinicians should incorporate into the management plan strategies to mitigate risk, including considering offering naloxone when factors that increase risk for opioid overdose, such as history of overdose, history of substance use disorder, higher opioid dosages (≥50 MME/day), or concurrent benzodiazepine use, are present.

(Recommendation category: A; Evidence type: 4)
TWO SOURCES OF RISK FOR LONG-TERM OPIOID THERAPY

- **Medication regimen**
  - Opioid dose
  - Long-acting or extended-release opioids
  - Concurrent sedative use

- **Patient characteristics**
  - Current or past substance use disorders (tobacco)
  - Inadequately treated mental health disorders (PTSD)
  - Young age
  - Previous opioid overdose
RISKS OF LONG-TERM OPIOID THERAPY TO PATIENTS

- Decreased function/return to work (cohorts)
- Hyperalgesia
- Tolerance (invisible?)
- Dependence (lifelong?)
- Misuse (due to above)
- Abuse (25%) and addiction (10%)
RISKS OF LONG-TERM OPIOID THERAPY TO PATIENTS

• Hypogonadism (infertility, low libido)
• Masked psychiatric disorder (PTSD)
• Induced depression (duration > dose)
• Overdose, death, emergency department visits (>700,000 in 2012)
• Motor vehicle crashes (OR=1.2-1.5)
• Falls, fractures, sedation, delirium
RISKS OF LONG-TERM OPIOID THERAPY TO FAMILY AND FRIENDS

• Abuse
  - 12th graders: 10% 2010 → 6% 2014

• Accidental overdose, death
  - Heroin deaths doubled 2010 – 2012

• Addiction
• Initially managed on gabapentin, began opioids in emergency department after motor vehicle crash

• These were continued because of reports of continued severe pain and dysfunction

• Opioid therapy slipped from short-term to long-term without explicit examination of goals, risks and benefits of long-term opioid therapy
Ms. Christie should not have been given more than 3-7 days of opioids for her back strain from motor vehicle crash.

When she saw her primary care provider 2 weeks later, her opioid therapy was now treating her FM, not her back strain from motor vehicle crash.

Her report of improvement a week after her primary care provider doubled her OxyContin dose, is not sounds promising, but is not a good indicator of her likelihood of benefit from long-term therapy.
FIBROMYALGIA REFERENCES


To Ask a Question

- **Using the Webinar System**
  - “Click” the Q&A tab at the top left of the webinar tool bar
  - “Click” in the white space
  - “Type” your question
  - “Click” ask

- **On the Phone**
  - Press Star (*) 1 to enter the queue
  - State your name
  - Listen for the operator to call your name
  - State your organization and then ask your question
Thank you for joining!

Centers for Disease Control and Prevention
Atlanta, Georgia

http://emergency.cdc.gov/coca
Today’s webinar will be archived

When:  A few days after the live call

What:  All call recordings (audio, webinar, and transcript)

Where:  On the COCA Call webpage

http://emergency.cdc.gov/coca/calls/2016/callinfo_080316.asp
Continuing Education for COCA Calls

All continuing education (CME, CNE, CEU, CECH, ACPE, CPH, and AAVSB/RACE) for COCA Calls are issued online through the CDC Training & Continuing Education Online system (http://www.cdc.gov/TCEOnline/).

Those who participated in today’s COCA Call and who wish to receive continuing education should complete the online evaluation by September 2, 2016 with the course code WC2286. Those who will participate in the on demand activity and wish to receive continuing education should complete the online evaluation between September 3, 2016 and August 2, 2018 will use course code WD2286.

Continuing education certificates can be printed immediately upon completion of your online evaluation. A cumulative transcript of all CDC/ATSDR CE’s obtained through the CDC Training & Continuing Education Online System will be maintained for each user.
Join the COCA Mailing List

Receive information about:
• Upcoming COCA Calls
• Health Alert Network notices
• CDC public health activations
• Emerging health threats
• Emergency preparedness and response conferences and training opportunities

http://emergency.cdc.gov/coca
## Save-the-Dates

Mark your calendar for the upcoming opioid prescribing call

<table>
<thead>
<tr>
<th>Call No.</th>
<th>Date</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>June 22</td>
<td>Guideline for Prescribing Opioids for Chronic Pain</td>
</tr>
<tr>
<td>2</td>
<td>July 27</td>
<td>Non-Opioid Treatments</td>
</tr>
<tr>
<td>3</td>
<td>August 3</td>
<td>Assessing Benefits and Harms of Opioid Therapy</td>
</tr>
<tr>
<td>4</td>
<td>August 17</td>
<td>Dosing and Titration of Opioids</td>
</tr>
</tbody>
</table>
Upcoming COCA Call registration is not required

Updated Interim Zika Clinical Guidance for Pregnant Women and Data on Contraceptive Use to Decrease Zika-affected Pregnancies

- Date: Tuesday, August 9, 2016
- Time: 2:00 – 3:00 pm (Eastern)
- Presenters:
  - Dr. Charlan D. Kroelinger – CDC
  - Dr. Erin Berry-Bibee – CDC
  - Dr. Titilope Oduyebo – CDC

http://emergency.cdc.gov/coca
Join Us on Facebook

CDC Facebook page for clinicians! “Like” our page today to learn about upcoming COCA Calls, CDC guidance and recommendations, and other health alerts

CDC Clinician Outreach and Communication Activity
https://www.facebook.com/CDCClinicianOutreachAndCommunicationActivity